Countries globally face major challenges in the early diagnosis and treatment of hypercholesterolaemia and cardiovascular disease, with numerous health inequities by geography and income. Perseverance, hard work, integrity and commitment can transform aspiration into reality. My PCSK9 story, from the discovery of its implication in familial hypercholesterolemia to the development of life-saving drugs, is a real example.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Achieving the vision of genomics to improve health for all requires a focus on diversity, equity and inclusion
Journal of Community Genetics Open Access 21 July 2025
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Varret, M. et al. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32. Am. J. Hum. Genet. 64, 1378–1387 (1999).
Haddad, L. et al. Evidence for a third genetic locus causing familial hypercholesterolemia. A non-LDLR, non-APOB kindred. J. Lipid Res. 40, 1113–1122 (1999).
Seidah, N. G. et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl Acad. Sci. USA 100, 928–933 (2003).
Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154–156 (2003).
Timms, K. M. et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum. Genet. 114, 349–353 (2004).
Cohen, J. et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161–165 (2005).
Benjannet, S. et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279, 48865–48875 (2004).
Abifadel, M. & Boileau, C. Genetic and molecular architecture of familial hypercholesterolemia. J. Intern. Med. 293, 144–165 (2023).
Abifadel, M. et al. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum. Mutat. 30, E682–E691 (2009).
Khachadurian, A. K. The inheritance of essential familial hypercholesterolemia. Am. J. Med. 37, 402–407 (1964).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Abifadel, M. Scientific journey from PSCK9 discovery in familial hypercholesterolaemia. Nat Rev Cardiol 22, 387–388 (2025). https://doi.org/10.1038/s41569-025-01147-w
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41569-025-01147-w
This article is cited by
-
Achieving the vision of genomics to improve health for all requires a focus on diversity, equity and inclusion
Journal of Community Genetics (2025)
